Neximmune Stock EBITDA
Neximmune fundamentals help investors to digest information that contributes to Neximmune's financial success or failures. It also enables traders to predict the movement of Neximmune Pink Sheet. The fundamental analysis module provides a way to measure Neximmune's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neximmune pink sheet.
Neximmune |
Neximmune Company EBITDA Analysis
Neximmune's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Neximmune EBITDA | (28.17 M) |
Most of Neximmune's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neximmune is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Neximmune reported earnings before interest,tax, depreciation and amortization of (28.17 Million). This is 103.21% lower than that of the Biotechnology sector and 128.12% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.72% higher than that of the company.
Neximmune EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neximmune's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Neximmune could also be used in its relative valuation, which is a method of valuing Neximmune by comparing valuation metrics of similar companies.Neximmune is currently under evaluation in ebitda category among its peers.
Neximmune Fundamentals
| Return On Equity | -1.96 | ||||
| Return On Asset | -0.7 | ||||
| Current Valuation | (491.95 K) | ||||
| Shares Outstanding | 1.37 M | ||||
| Shares Owned By Insiders | 17.00 % | ||||
| Shares Owned By Institutions | 11.17 % | ||||
| Number Of Shares Shorted | 15.99 K | ||||
| Price To Book | 1.38 X | ||||
| EBITDA | (28.17 M) | ||||
| Net Income | (32.34 M) | ||||
| Cash And Equivalents | 53.13 M | ||||
| Cash Per Share | 2.20 X | ||||
| Total Debt | 68.81 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 6.54 X | ||||
| Book Value Per Share | 2.00 X | ||||
| Cash Flow From Operations | (31.43 M) | ||||
| Short Ratio | 2.26 X | ||||
| Earnings Per Share | (24.11) X | ||||
| Target Price | 2.0 | ||||
| Beta | 1.94 | ||||
| Market Capitalization | 3.25 M | ||||
| Total Asset | 8.59 M | ||||
| Retained Earnings | (222.59 M) | ||||
| Working Capital | 316.73 K | ||||
| Net Asset | 8.59 M |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in Neximmune Pink Sheet
If you are still planning to invest in Neximmune check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neximmune's history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |